- A scientific-data oral presentation, two posters and a symposium presentation will highlight the clinical and research advantages of the company’s Afirma molecular test and capabilities - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 12, 2023-- Veracyte, Inc.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 25, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate the ability of the company’s Decipher Genomics Resource for Intelligent Discovery
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 24, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in two upcoming investor conferences: William Blair 43 rd Annual Growth Stock
Findings from prospective, population-based study presented at ESMO Breast Cancer Congress 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for
Grew Total Revenue to $82.4 million , an Increase of 22% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023 .
Findings reinforce value of Veracyte’s expanded Afirma offering, which now includes TERT gene mutation testing SOUTH SAN FRANCISCO--(BUSINESS WIRE)--May 4, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 3, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that data published in the journal Cancer show the ability of a novel gene expression signature to classify prostate cancer into distinct molecular subtypes that may inform which tumors are more
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 3, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report . The 2023 ESG Report sets the foundation for Veracyte’s ESG performance and outlines the company’s ambitions
Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that data published in the International
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
